HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis labeling changes

This article was originally published in The Tan Sheet

Executive Summary

Labeling of firm's Transderm Scop Rx motion sickness patch modified to remove statement claiming superiority over Pharmacia's OTC remedy Dramamine (oral dimenhydrinate), according to FDA's May 10 letter responding to Pharmacia petition. Agency determined comparative statement "is not supported by any data in Novartis' [NDA] for Transderm Scop," and requested it be removed from labeling. Novartis complied in a labeling supplement approved March 22. Novartis also removed superiority claim from DTC print ads, Web site after National Advertising Division determined evidence was insufficient to support the statement (1"The Tan Sheet" Nov. 13, 2000, p. 11)...

You may also be interested in...



Novartis Transderm Scop Comparative Claims With Dramamine Denied By NAD

DTC ad claims for Novartis' Rx Transderm Scop declaring superiority to Pharmacia's OTC motion sickness remedy Dramamine are inappropriate due to "very significant differences" between the scopolamine patch's consumer-targeted claims and original FDA-reviewed statements, NAD states Nov. 8.

PDUFA Renewal Negotiations: What Does Industry Want Now?

With the formal, virtual kick-off meeting set for 23 July, US FDA and sponsors are looking at a transformed landscape as they discuss what the next five years of user fees will look like.

Keeping Track: Approvals For Phexxi, Kynombi; New Claims For Lynparza, Alunbrig, Tecentriq; Intercept May Miss NASH User Fee Date

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

SC142283

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel